Sodium Methanesulfinate CAS 20277-69-4 Purity >96.0% Factory High Purity

Short Description:

Chemical Name: Sodium Methanesulfinate 

CAS: 20277-69-4

Appearance: White or Off-White Crystal Powder

Purity: >96.0%  

Contact: Dr. Alvin Huang 

Mobile/Wechat/WhatsApp: +86-15026746401  

E-Mail: alvin@ruifuchem.com 


Product Detail

Related Products

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Sodium Methanesulfinate (CAS: 20277-69-4) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Sodium Methanesulfinate, Please contact: alvin@ruifuchem.com

Lapatinib Intermediates:

Chemical Properties:

Chemical Name Sodium Methanesulfinate
Synonyms Methanesulfinic Acid Sodium Salt
CAS Number 20277-69-4
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula CH5NaO2S
Molecular Weight 104.1
Melting Point 222.0~226.0℃(dec.) (lit.)
Water Solubility Soluble in Water 
Sensitive Air Sensitive & Hygroscopic
COA & MSDS Available
Origin Shanghai, China
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Crystal Powder
Purity >96.0%
Loss on drying <1.00%
Infrared Spectrum Conforms to Structure
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates; Organic Synthesis

Package & Storage:

3

Advantages:

10

FAQ:

www.ruifuchem.com

20277-69-4 - Risk and Safety:

Hazard Symbols Xn - Harmful 
Risk Codes R22 - Harmful if swallowed
R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed.
Safety Description  S36/37 - Wear suitable protective clothing and gloves.
S24/25 - Avoid contact with skin and eyes.
UN IDs  2811
WGK Germany 3
Packing Group  III

20277-69-4 - Application:

Shanghai Ruifu Chemical Co., Ltd. commercial supply Sodium Methanesulfinate (CAS: 20277-69-4). It is an important pharmaceutical intermediate, which can be used in the prodcution of API (CAS 231277-92-2) and (CAS 388082-78-8) API or other intermediates. (CAS 388082-78-8), a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. It has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination with Capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. 

  • Write your message here and send it to us